The fall in estrogen levels after menopause is a major driver of osteoporosis, leaving many women at higher risk of fractures. A new study shows how a bone-targeted delivery system could restore strength while reducing side effects.
Estrogen is important for healthy bones, from growth and maturation to the fine balance of bone turnover in adulthood. As women enter menopause, estrogen levels drop and bones become more fragile, increasing the risk of fractures. Some women turn to hormone replacement therapy (HRT) to help lower fracture risk, but standard estrogen treatments send the hormone throughout the body, which can cause unwanted side effects in other tissues and often don’t deliver enough to the bones themselves.
A smarter delivery method
To address this, researchers have been looking at ways to direct estrogen specifically to bone, avoiding other organs. The latest research, published in Nano Letters, introduces a clever solution: a two-part delivery system designed to release estrogen right at the site of bone loss.
The researchers started with a coacervate—a tiny, liquid-like compartment made from peptides (short chains of amino acids) that naturally seek out calcium-rich bone. Inside this coacervate, they packed estradiol, the form of estrogen most important for bone health. To protect the cargo and control its release, they wrapped the coacervate in a metal–phenolic network (MPN) made from tannic acid and magnesium ions. This shell is designed to stay intact in the bloodstream but break apart in the acidic environment found in osteoporotic bone. When the shell dissolves, it releases estradiol, tannic acid, and magnesium right where bone is most vulnerable. Tannic acid helps calm inflammation and slow down bone breakdown, while magnesium supports bone-building cells.
Unlocking targeted treatment
In tests, the double-layered system remained stable in neutral conditions, releasing its contents only when the environment turned acidic—just like in bone affected by osteoporosis. The team then tested the system in mice that had lost bone density due to menopause-like changes. Mice received regular injections of the bone-targeted estrogen, standard estrogen, or a placebo.
The mice treated with the bone-targeted system saw their bone density rebound in both the femur and vertebrae, showing no signs of the uterine side effects that often come with regular estrogen therapy. Imaging confirmed that the treatment concentrated in weakened bone, not elsewhere in the body.
This work points to an effective new way to treat osteoporosis by sending estrogen directly to where it’s needed most, while sparing other tissues. It’s an early-stage, preclinical study, so more work is needed before this approach can be tested in humans. The researchers hope to develop an oral version of the double-coated estrogen pill in the future.
Explore related research in ACS journals:
Regulation of Bone Remodeling by Metal–Phenolic Networks for the Treatment of Systemic Osteoporosis
Xi Chen*, Weihui Wu, Wei Zhu, Jiajing Zhou, Jingqu Chen, Zhixing Lin, Sixian Zhang, Frank Caruso*, and Changsheng Liu*
DOI: 10.1021/acsami.4c18829
Rectifying the Crosstalk between the Skeletal and Immune Systems Improves Osteoporosis Treatment by Core–Shell Nanocapsules
Chunting He, Penghui He, Yangsen Ou, Xue Tang, Hongjiao Wei, Yanhua Xu, Shuting Bai, Zhaofei Guo, Rui Hu, Kun Xiong, Guangsheng Du, and Xun Sun*
DOI: 10.1021/acsnano.4c14728
A POSS-Based Metal-Phenolic Network with Coupled Hardness and Softness for Photodynamic-Immunotherapy of Triple-Negative Breast Cancer
Wei Wang, Luanfeng Liao, Yun Huang, Yuqi Zhao, Longtianyang Lei, Zhenghao Tao, Jinyan Zhang, Dongdong Peng, Jie-Qiong Wang, Cui-Yun Yu*, and Hua Wei*
DOI: 10.1021/acsmaterialslett.4c00661
Large Model Era: Deep Learning in Osteoporosis Drug Discovery
Junlin Xu, Xiaobo Wen, Li Sun, Kunyue Xing, Linyuan Xue, Sha Zhou, Jiayi Hu, Zhijuan Ai, Qian Kong, Zishu Wen, Li Guo*, Minglu Hao*, and Dongming Xing*
DOI: 10.1021/acs.jcim.4c02264
A Metal–Phenolic Network Nanoresensitizer Overcoming Glioblastoma Drug Resistance through the Metabolic Adaptive Strategy and Targeting Drug-Tolerant Cells
Na Yin, Bin Wang, Yinghui Wang*, Long Tian, Songrun Han, Boxin Zheng, Fei Feng, Shuyan Song*, and Hongjie Zhang*
DOI: 10.1021/acs.nanolett.5c01141
Interface-Engineered Polystyrene-Divinylbenzene Microspheres with Polyethylenimine and Metal-Phenolic Networks for Multifunctional Sepsis Hemoperfusion
Xingqiang Zhu, Wenjing Song*, Ye Tian, Zhuhao Tan, Baolei Huang, Hailin Zhang, Anmin Wang, Wenfang Liu, Wei Zhai, and Li Ren*
DOI: 10.1021/acsami.5c06712
